India has granted market authorisation to Takeda Biopharmaceuticals’ dengue vaccine QDENGA, making it the country’s first approved vaccine for dengue prevention. The approval by CDSCO follows extensive global and Indian clinical trials confirming its safety and efficacy.
Hyderabad’s AIIMS Bibinagar has emerged as a crucial site for India’s first indigenous dengue vaccine, currently in phase III clinical trials. Led by ICMR and developed in partnership with Panacea Biotec, the single-shot tetravalent vaccine is in its final phase of enrollment.
While development of a dengue vaccine has been perennially in the making, the recent launch of the third phase of clinical trials of dengue vaccine in India by ICMR with Panacea Biotec, has raised hopes over the availability of a dengue vaccine to the general public in the next few years.
